ArticleGynecologic oncology reports2026
Real-world efficacy and safety of cemiplimab in Japanese patients with recurrent or metastatic cervical cancer: A single-center retrospective cohort study.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the real-world efficacy and safety of cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer (R/M CC), including patients from subgroups underrepresented in clinical trials.
methodsWe conducted a single-center, retrospective cohort study of 25 consecutive patients with R/M CC treated with cemiplimab between April 2023 and April 2025. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Responses were assessed by RECIST version 1.1, and treatment-emergent adverse events (TEAEs) were graded according to CTCAE version 5.0.
resultsThe median follow-up was 12.6 months. The ORR was 16.0% (95% CI, 4.5-36.1%) and the DCR was 64.0% (95% CI, 42.5-82.0%). The median PFS was 2.8 months (95% CI, 2.1-3.5), and the median OS was 12.6 months (95% CI, 5.1-20.1). All patients with recurrence confined to a previously irradiated field achieved disease control. No treatment-related deaths occurred.
conclusionsCemiplimab demonstrated manageable toxicity and clinically meaningful disease control in routine practice, including patients with biologically aggressive tumors or recurrences in previously irradiated fields.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.